Last reviewed · How we verify

Albendazole on Day 1

Lihir Medical Centre · Phase 3 active Small molecule

Albendazole on Day 1 is a Benzimidazole anthelmintic Small molecule drug developed by Lihir Medical Centre. It is currently in Phase 3 development for Soil-transmitted helminth infections (Ascaris lumbricoides, Trichuris trichiura, Necator americanus, Ancylostoma duodenale), Cysticercosis (neurocysticercosis), Echinococcosis (hydatid disease). Also known as: Albenza.

Albendazole inhibits microtubule polymerization in parasitic worms by binding to β-tubulin, disrupting their cytoskeletal structure and causing paralysis and death.

Albendazole inhibits microtubule polymerization in parasitic worms by binding to β-tubulin, disrupting their cytoskeletal structure and causing paralysis and death. Used for Soil-transmitted helminth infections (Ascaris lumbricoides, Trichuris trichiura, Necator americanus, Ancylostoma duodenale), Cysticercosis (neurocysticercosis), Echinococcosis (hydatid disease).

At a glance

Generic nameAlbendazole on Day 1
Also known asAlbenza
SponsorLihir Medical Centre
Drug classBenzimidazole anthelmintic
Targetβ-tubulin
ModalitySmall molecule
Therapeutic areaInfectious Disease / Parasitology
PhasePhase 3

Mechanism of action

Albendazole is a benzimidazole anthelmintic that selectively binds to β-tubulin in parasitic nematodes and cestodes, preventing microtubule assembly. This disrupts glucose uptake and energy metabolism in the parasite, leading to immobilization and eventual death. The drug has selective toxicity for parasites over mammalian cells due to differences in tubulin binding affinity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Albendazole on Day 1

What is Albendazole on Day 1?

Albendazole on Day 1 is a Benzimidazole anthelmintic drug developed by Lihir Medical Centre, indicated for Soil-transmitted helminth infections (Ascaris lumbricoides, Trichuris trichiura, Necator americanus, Ancylostoma duodenale), Cysticercosis (neurocysticercosis), Echinococcosis (hydatid disease).

How does Albendazole on Day 1 work?

Albendazole inhibits microtubule polymerization in parasitic worms by binding to β-tubulin, disrupting their cytoskeletal structure and causing paralysis and death.

What is Albendazole on Day 1 used for?

Albendazole on Day 1 is indicated for Soil-transmitted helminth infections (Ascaris lumbricoides, Trichuris trichiura, Necator americanus, Ancylostoma duodenale), Cysticercosis (neurocysticercosis), Echinococcosis (hydatid disease), Strongyloidiasis.

Who makes Albendazole on Day 1?

Albendazole on Day 1 is developed by Lihir Medical Centre (see full Lihir Medical Centre pipeline at /company/lihir-medical-centre).

Is Albendazole on Day 1 also known as anything else?

Albendazole on Day 1 is also known as Albenza.

What drug class is Albendazole on Day 1 in?

Albendazole on Day 1 belongs to the Benzimidazole anthelmintic class. See all Benzimidazole anthelmintic drugs at /class/benzimidazole-anthelmintic.

What development phase is Albendazole on Day 1 in?

Albendazole on Day 1 is in Phase 3.

What are the side effects of Albendazole on Day 1?

Common side effects of Albendazole on Day 1 include Abdominal pain, Diarrhea, Nausea, Headache, Dizziness, Elevated liver enzymes.

What does Albendazole on Day 1 target?

Albendazole on Day 1 targets β-tubulin and is a Benzimidazole anthelmintic.

Related